Vaccines Today—July 3, 2026

This week’s Vaccine and Immunotherapy update highlights regulatory progress, positive clinical data, platform innovation, manufacturing expansion, and mixed trial outcomes across cancer, infectious disease, and maternal immunization.

In Today’s Newsletter

Dive deeper

💉 Anixa breast cancer vaccine and lira-cel updates [1] [US • 26 Jun 2026]

https://ir.anixa.com/press-releases/detail/1127/anixa-biosciences-reports-positive-data-from-completed
Context: Anixa Biosciences presented its breast cancer vaccine and lira-cel ovarian cancer CAR-T programme at the New York Academy of Sciences symposium.
Key point: The breast cancer vaccine met all major primary endpoints and generated protocol-defined immune responses in 74% of participants.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Zelluna closes legacy UV1 programme after DOVACC miss [2] [Norway • 26 Jun 2026]

https://zelluna.com/investors/news/readout-from-legacy-ultimovacs-dovacc-phase-ii-trial-concludes-uv1-programme-as-previously-guided
Context: DOVACC evaluated UV1 in BRCAwt platinum-sensitive recurrent ovarian cancer alongside established cancer medicines.
Key point: The Phase 2 trial did not meet its primary PFS endpoint, and Zelluna now considers the UV1 programme closed.
Implication: Signals pipeline investment and modality expansion.

🤰 Sanofi Korea Adacel pregnancy indication approved [3] [South Korea • 05 Jun 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=32223
Context: MFDS approved Adacel Prefilled Syringe for use at 27–36 weeks of gestation.
Key point: The expanded indication supports maternal immunization to provide passive pertussis protection for newborns.
Implication: May expand screening, initiation, and follow-up at scale.

👃 AdJane nOMV platform shows mucosal immunity in humans [4] [Netherlands • 30 Jun 2026]

https://adjane.com/news/adjane-reports-first-clinical-validation/
Context: The first-in-human randomized, double-blind, placebo- and OMV-controlled Phase 1 trial enrolled 40 healthy adults.
Key point: AdJane’s intranasal nOMV platform was safe and well tolerated and induced systemic and mucosal immune responses.
Implication: May influence prescriber choice and payer reviews pending full data.

📜 Anixa Korean breast cancer vaccine patent issued [5] [South Korea • 29 Jun 2026]

https://ir.anixa.com/press-releases/detail/1128/anixa-biosciences-granted-first-korean-patent-for-its
Context: The Korean Ministry of Intellectual Property issued Patent No. 10-2960889 for Anixa’s breast cancer vaccine technology.
Key point: The composition-of-matter patent, licensed from Cleveland Clinic, protects the technology in South Korea through 2040.
Implication: Signals pipeline investment and modality expansion.

🏭 Likang AI-assisted personalized tumor vaccine line breaks ground [6] [China • 29 Jun 2026]

https://www.indexbox.io/blog/chinas-first-ai-assisted-personalized-tumor-vaccine-production-line-breaks-ground/
Context: Likang Life Sciences is building a research and manufacturing center in Beijing Economic and Technological Development Zone.
Key point: The facility will include a production line for LK101, a personalized tumor vaccine using AI to analyze tumor DNA.
Implication: Signals pipeline investment and modality expansion.

🪱 SchistoShield shows immune memory in early trials [7] [US, Africa • 29 Jun 2026]

https://www.genengnews.com/topics/infectious-diseases/schistosomiasis-vaccine-shows-strong-immune-memory-in-early-clinical-trials/
Context: SchistoShield (Sm-p80 + GLA-SE) completed Phase 1 in the US and Phase 1b in Africa.
Key point: Trial samples showed adaptive immune effector and memory responses, including B-cell and T-cell-based memory.
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 WRSs2 Shigella vaccine reports Phase 2 protection [8] [US • 30 Jun 2026]

https://www.biopharminternational.com/view/phase-2-trial-of-wrss2-shigella-vaccine-shows-89-protection-offering-hope-against-antibiotic-resistant-pathogen
Context: The randomized, double-blind, placebo-controlled controlled human infection trial enrolled 108 healthy adults.
Key point: Two WRSs2 doses provided 89% protection against Shigella sonnei infection, with no vaccine-related serious adverse events reported.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Cancer vaccines remain active across preventive, personalized, and immune-targeted approaches, with Anixa and Likang highlighting different development models.
Negative Phase 2 readouts still shape the field, as Zelluna’s UV1 closure narrows focus toward TCR-NK cell therapy.
Maternal immunization continues to expand as a newborn protection strategy, shown by Sanofi Korea’s Adacel approval.
Mucosal vaccine platforms are gaining clinical validation, with AdJane targeting respiratory infections and pandemic preparedness.
Enteric and parasitic disease vaccines remain important for antimicrobial resistance and neglected disease preparedness.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page.

FAQ

What did Anixa Biosciences report for its breast cancer vaccine?

Anixa said its Phase 1 breast cancer vaccine trial met all major primary endpoints and generated protocol-defined immune responses in 74% of participants [1].

Why did Zelluna close the UV1 programme?

Zelluna said the DOVACC Phase 2 trial in BRCAwt platinum-sensitive recurrent ovarian cancer did not meet its primary PFS endpoint. It said all five Phase 2 UV1 studies missed their primary endpoints [2].

What changed for Sanofi Korea’s Adacel?

MFDS expanded Adacel’s indication for use during pregnancy, allowing administration at 27–36 weeks of gestation to help protect newborns against pertussis [3].

What did AdJane’s Phase 1 data show?

AdJane reported that its intranasal nOMV platform was safe and well tolerated in 40 healthy adults and induced both systemic and mucosal immune responses [4].

What is Likang Life Sciences building in China?

Likang is building a Beijing research and manufacturing center that will include a production line for LK101, an AI-assisted personalized tumor vaccine [6].

What did the WRSs2 Shigella trial report?

The Phase 2 controlled human infection trial reported 89% protection against Shigella sonnei infection after two doses, with no vaccine-related serious adverse events reported [8].

Entities / Keywords

Anixa Biosciences: ANIX, breast cancer vaccine, α-lactalbumin vaccine, Cleveland Clinic, lira-cel, liraltagene autoleucel, ovarian cancer CAR-T, FSHR, Moffitt Cancer Center
Zelluna: ZLNA, Ultimovacs, UV1, DOVACC, BRCAwt platinum-sensitive recurrent ovarian cancer, TCR-NK, ZI-MA4-1
Sanofi Korea: Adacel, Adacel Prefilled Syringe, Tdap, pertussis, maternal immunization, MFDS, KDCA
AdJane: nOMV, native outer membrane vesicles, intranasal vaccine, mucosal immunity, SARS-CoV-2 Spike, CEPI, CARB-X
Likang Life Sciences: LK101, AI-assisted personalized tumor vaccine, tumor DNA, Beijing Economic and Technological Development Zone
SchistoShield: Sm-p80 + GLA-SE, schistosomiasis vaccine, TTUHSC, immune memory, B-cell response, T-cell response
WRSs2: Shigella sonnei, live-attenuated oral vaccine, controlled human infection model, WRAIR, NIAID, Cincinnati Children’s